Squamous Cell Lung CarcinomaSymptoms, Doctors, Treatments, Advances & More
Learn About Squamous Cell Lung Carcinoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Medical Oncology - Swedish Cancer Institute First Hill
Dr. Somasundaram Subramaniam is a Medical Oncologist at the Swedish Cancer Institute in Seattle, Washington and a 2021 Seattle Met Top Doctor Award winner. He has specialized expertise in the management of Gastrointestinal (GI) Cancers. This includes common cancers like colon and rectal cancers and also less common cancers like stomach cancer, neuroendocrine tumors (NETs) and liver and bile duct cancers. He also treats patients with lung cancer and kidney cancer. Dr. Soma chose to pursue a career in Oncology to help patients diagnosed with very serious illnesses and their families by providing hope, education and the best opportunities for treatment and cure. He is thrilled to be working with at Swedish, which has an excellent group of caring and highly-trained physicians, nurses and providers who all work very closely together with a robust multi-disciplinary team approach.. Dr. Subramaniam is an investigator on several clinical trials and a key member of the Personalized Medicine Research Program at Swedish, which focuses on the using a tumor’s DNA mutations to target it with newer drugs. The Swedish Cancer Institute prioritizes opening cutting-edge clinical trials to ensure patients have access to the latest innovations in cancer therapy. Dr. Subramaniam graduated from medical school at the National University of Singapore and obtained sub-specialty training during his fellowship at Stanford University, which was supported by a T32 training grant awarded by the National Institutes of Health. He is board-certified in Internal Medicine and Medical Oncology. Dr. Subramaniam also earned a Master of Science degree in Epidemiology and Clinical Research from Stanford. In addition to treating patients with cancer, Dr. Subramaniam is the Medical Director of the Cancer Control program, which emphasizes preventative measures and appropriate cancer screening, to reduce the incidence and burden of cancer in our community. Dr. Subramaniam is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, ALK-Positive Non-Small Cell Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Subramaniam is board certified in American Board Of Internal Medicine. Dr. Subramaniam is currently accepting new patients.
Vince Lombardi Cancer Clinic
Demet Yasar is a Hematologist practicing medicine in Green Bay, Wisconsin. Dr. Yasar is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. She is also highly rated in 51 other conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Myelodysplastic Syndrome (MDS). Dr. Yasar is board certified in American Board Of Internal Medicine, Hematology.
Advocate Lutheran General Cancer Institute
Jason Macklis is a Hematologist and an Oncologist practicing medicine in Park Ridge, Illinois. Dr. Macklis is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Bone Marrow Aspiration. Dr. Macklis is board certified in American Board Of Internal Medicine, Hematology.
Summary: A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Summary: This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium \[177Lu\] BL-ARC001 in patients with locally advanced or metastatic solid tumors.